과제정보
This work was supported by Hunan Provincial Nature (No. 2019JJ40264): Effects of H2S on cardiac Warburg effect and atrial fibrillation through sulfhydrylation of PKM2 and Hunan Provincial Health Commission project (No. C202303019609): Effects of H2S targeting miR-133a mediating TGF-β1 pathway on atrial fibrillation and atrial fibrosis.
참고문헌
- Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther 2010;128:191-227.
- Shimizu I, Minamino T. Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol 2016;97:245-62.
- Lei H, Hu J, Sun K, Xu D. The role and molecular mechanism of epigenetics in cardiac hypertrophy. Heart Fail Rev 2021;26:1505-14.
- Sawicka KM, Florek-Luszczki M, Wawryniuk A, et al. Dronedarone (a multichannel blocker) enhances the anticonvulsant potency of lamotrigine, but not that of lacosamide, pregabalin and topiramate in the tonic-clonic seizure model in mice. Epilepsy Res 2019;154:62-8.
- Quintana-Villamandos B, Gomez de Diego JJ, Delgado-Martos MJ, et al. Dronedarone produces early regression of myocardial remodelling in structural heart disease. PLoS One 2017;12:e0188442.
- Ding RB, Bao J, Deng CX. Emerging roles of SIRT1 in fatty liver diseases. Int J Biol Sci 2017;13:852-67.
- Hajializadeh Z, Khaksari M. The protective effects of 17-β estradiol and SIRT1 against cardiac hypertrophy: a review. Heart Fail Rev 2022;27:725-38.
- Sundaresan NR, Pillai VB, Gupta MP. Emerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophy. J Mol Cell Cardiol 2011;51:614-8.
- Li S, Zhu Z, Xue M, et al. Fibroblast growth factor 21 protects the heart from angiotensin II-induced cardiac hypertrophy and dysfunction via SIRT1. Biochim Biophys Acta Mol Basis Dis 2019;1865:1241-52.
- Di Vincenzo S, Heijink IH, Noordhoek JA, et al. SIRT1/FoxO3 axis alteration leads to aberrant immune responses in bronchial epithelial cells. J Cell Mol Med 2018;22:2272-82.
- Yao H, Chung S, Hwang JW, et al. SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice. J Clin Invest 2012;122:2032-45.
- Yao J, Wang J, Xu Y, et al. CDK9 inhibition blocks the initiation of PINK1-PRKN-mediated mitophagy by regulating the SIRT1-FOXO3-BNIP3 axis and enhances the therapeutic effects involving mitochondrial dysfunction in hepatocellular carcinoma. Autophagy 2022;18:1879-97.
- Song G, Zhu L, Ruan Z, Wang R, Shen Y. MicroRNA-122 promotes cardiomyocyte hypertrophy via targeting FoxO3. Biochem Biophys Res Commun 2019;519:682-8.
- Liu Y, Chen J, Fontes SK, Bautista EN, Cheng Z. Physiological and pathological roles of protein kinase A in the heart. Cardiovasc Res 2022;118:386-98.
- Zhang X, Szeto C, Gao E, et al. Cardiotoxic and cardioprotective features of chronic β-adrenergic signaling. Circ Res 2013;112:498-509.
- Xu J, Han Q, Shi H, Liu W, Chu T, Li H. Role of PKA in the process of neonatal cardiomyocyte hypertrophy induced by urotensin II. Int J Mol Med 2017;40:499-504.
- Hoy JJ, Salinas Parra N, Park J, Kuhn S, Iglesias-Bartolome R. Protein kinase A inhibitor proteins (PKIs) divert GPCR-Gαs-cAMP signaling toward EPAC and ERK activation and are involved in tumor growth. FASEB J 2020;34:13900-17.
- Sotomayor-Flores C, Rivera-Mejias P, Vasquez-Trincado C, et al. Angiotensin-(1-9) prevents cardiomyocyte hypertrophy by controlling mitochondrial dynamics via miR-129-3p/PKIA pathway. Cell Death Differ 2020;27:2586-604.
- White PM. The role of the transcription factor Foxo3 in hearing maintenance: informed speculation on a new player in the cochlea. BioMed Res Int 2016;2016:1870675.
- Ren B, Feng J, Yang N, Guo Y, Chen C, Qin Q. Ginsenoside Rg3 attenuates angiotensin II-induced myocardial hypertrophy through repressing NLRP3 inflammasome and oxidative stress via modulating SIRT1/NF-κB pathway. Int Immunopharmacol 2021;98:107841.
- Vamos M, Hohnloser SH. Amiodarone and dronedarone: an update. Trends Cardiovasc Med 2016;26:597-602.
- Li H, Zhou Y, Jiang B, et al. Dual effects of amiodarone on pacemaker currents in hypertrophied ventricular myocytes isolated from spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2014;41:698-707.
- Takach TJ, Voigtlander JP, Jones M, Clark RE. Myocardial protective effect of amiodarone in hypertrophied hearts during global ischemia. Ann Thorac Surg 1986;41:542-6.
- Zimetbaum PJ. Dronedarone for atrial fibrillation--an odyssey. N Engl J Med 2009;360:1811-3.
- Chen H, Chen X, Sun P, et al. Discovery of dronedarone and its analogues as NLRP3 inflammasome inhibitors with potent anti-inflammation activity. Bioorg Med Chem Lett 2021;46:128160.
- Li Y, Ruan X, Xu X, et al. Shengmai injection suppresses angiotensin II-induced cardiomyocyte hypertrophy and apoptosis via activation of the AMPK signaling pathway through energy-dependent mechanisms. Front Pharmacol 2019;10:1095.
- Cheng Y, Shen A, Wu X, et al. Qingda granule attenuates angiotensin II-induced cardiac hypertrophy and apoptosis and modulates the PI3K/AKT pathway. Biomed Pharmacother 2021;133:111022.
- Zhu C, Wang M, Yu X, et al. lncRNA NBR2 attenuates angiotensin II-induced myocardial hypertrophy through repressing ER stress via activating LKB1/AMPK/Sirt1 pathway. Bioengineered 2022;13:13667-79.
- Liu Z, Li C, Yu C, Chen Z, Zhao C, Ye L. TSPYL2 reduced gefitinib resistance and DNA damage repair via suppressing SIRT1-mediated FOXO3 deacetylation. Future Med Chem 2022;14:407-19.
- Senger N, C Parletta A, Marques BV, et al. Angiotensin-(1-7) prevents T3-induced cardiomyocyte hypertrophy by upregulating FOXO3/SOD1/catalase and downregulating NF-κB. J Cell Physiol 2021;236:3059-72.